Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Amortization of Deferred Charges (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $59000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortization of Deferred Charges changed N/A to $59000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $154000.0, a N/A change, with the full-year FY2024 number at $31000.0, down 72.32% from a year prior.
  • Amortization of Deferred Charges was $59000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $46000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $59000.0 in Q3 2025 to a low of $3000.0 in Q4 2023.
  • A 3-year average of $38727.3 and a median of $36000.0 in 2022 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 2.78% in 2023; the steepest drop was 91.67% in 2023.
  • Orchestra BioMed Holdings' Amortization of Deferred Charges stood at $36000.0 in 2022, then plummeted by 91.67% to $3000.0 in 2023, then soared by 1866.67% to $59000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Amortization of Deferred Charges are $59000.0 (Q3 2025), $46000.0 (Q2 2025), and $46000.0 (Q1 2025).